Eflapegrastim, Spectrum's third biological drug, is a long-acting Granulocyte-Colony Stimulating Factor (G-CSF) that utilizes Hanmi Pharmaceutical Co., Ltd. proprietary platform technology, LAPSCOVERY™1.
Chemotherapy can cause myelosuppression and unacceptably low levels of white blood cells, making patients prone to infections, hospitalizations, and interruption of additional chemotherapy treatments. G-CSF stimulates proliferation of granulocyte progenitors and subsequent production of neutrophils in the bone marrow. A recombinant form of G-CSF is used in appropriate cancer patients to accelerate recovery from neutropenia after chemotherapy, allowing higher-intensity treatment regimens to be given at full-dose and on schedule.
Route of Administration
Mode of Action
Binds to the G-CSF receptor expressed on granulocyte progenitors and stimulates their proliferation and subsequent maturation to functionally active neutrophils.
1. LAPSCOVERY is a trademark of Hanmi Pharmaceutical Co., Ltd.
Eflapegrastim is being tested for granulocyte recovery in patients with chemotherapy induced neutropenia, a multibillion dollar worldwide market.
If eflapegrastim is ultimately commercialized, Spectrum shall own worldwide rights except for Korea, China, and Japan.